Anne Wojcicki of 23andMe at FDA Public Meeting on LDTs, July 20, 2010

Direct-to-Consumer Genetic Information
Anne Wojcicki
Co-Founder

The 23andMe Service
Health and traits
Traits (Lactose tolerance, eye color)
Disease risks (VTE, macular degeneration)
Carrier status (Cystic Fibrosis, PKU)
Drug response (Warfarin, Clopidogrel)
Ancestry
Relative Finder
Ancestry Finder
Y and Mito Haplogroups
Copyright © 2010 23andMe, Inc. All rights reserved.

Who learns what? Venous thromboembolism: F5 or F2 carrier 8.2% Cystic fibrosis carrier 4% Substantially lower odds of responding to IFN-alpha 3.5% Greatly reduced Clopidogrel efficacy 3.1% Alpha-1 antitrypsin deficiency carrier 2.9% Sensorineural hearing loss carrier 1.8% Substantially increased Warfarin dose 0.5% Parkinson’s disease: LRRK2 carrier 0.5% Tay-Sachs carrier 0.4% Sickle cell trait 0.3% BRCA1 or BRCA2 carrier 0.2%

Context for Disease Risk John Doe

What to do next Ask your doctor about screening tests Estimate your risk Keep your weight in check Learn your family medical history Connect with relevant groups Talk with a genetic counselor

The Parkinson’s Project: July 2010 World's largest database of individuals with LRRK2 genotype ~4000 participants Over 75% have completed the Parkinson’s surveys 23andMe Proprietary/Confidential Copyright © 2010 23andMe, Inc. All rights reserved.

“ As for this site, it makes me feel like I am not alone, there is someone out there I can talk to, even if it is just to compare symptoms. Even though I have become actively involved in 2 PD groups, these conversations really help. Thank you to everyone who takes the time to read and reply.” 23andMe Proprietary/Confidential Copyright © 2010 23andMe, Inc. All rights reserved.

23andWe
23andMe Proprietary/Confidential Copyright © 2010 23andMe, Inc. All rights reserved.

Year one research results
Our internal pipeline runs hundreds of GWAS, nightly to generate updated statistics.
Recent replications:
Cholesterol : APOE, APOB, LDLR, PSRC1
Psoriasis : HLA
Gall stones : ABCG8
Parkinson's : SNCA and LRRK2
Obesity: FTO
Type 2 diabetes: TCF7L2
Lactose intolerance : LCT
Baldness : AR
23andMe Proprietary/Confidential Copyright © 2010 23andMe, Inc. All rights reserved.

Instant Replications (Or Not!)

Challenges for DTC
Involve physicians and health care providers
Standards for analytical and clinical validity, privacy
Understanding of what real harms and benefits might be
Framework for reporting genetic information
Maintaining consumer protection as the industry grows

Conclusion DTC genetic industry—like the entire genetic industry— needs a clear and rational regulatory oversight framework that also allows companies to contribute meaningfully to personalized medicine and improved health care .

http://spittoon.23andme.com	432
http://blog.23andme.com	36
https://blog.23andme.com	3
http://flyproxy5.appspot.com	1
http://translate.googleusercontent.com	1

Anne Wojcicki of 23andMe at FDA Public Meeting on LDTs, July 20, 2010

by The Spittoon

Accessibility

Upload Details

Usage Rights

5 Embeds 473

Statistics

Anne Wojcicki of 23andMe at FDA Public Meeting on LDTs, July 20, 2010 Presentation Transcript